AC Immune SA
Veridion Score
Composite trend over time
Why is ACIU moving today?
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ACIU.
ACIU insider activity
AC Immune SA
No multi-insider buying cluster in the last 90 days
Net selling: -$28K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | 2026-05-15 | Pfeifer Andrea | Insider | sell | $2.79 | 10,000 | 3,820,288 | $28K | SEC Form 4 |
| 2026-04-16 | 2026-04-15 | Pfeifer Andrea | Insider | sell | $3.14 | 10,000 | 3,830,288 | $31K | SEC Form 4 |
| 2026-04-16 | 2026-04-15 | Pfeifer Andrea | Insider | buy | $3.14 | 10,000 | 3,830,288 | $31K | SEC Form 4 |
ACIU contract awards, year to date.
Public federal awards linked to this ticker.
ACIU lobbying filings, year to date.
Registered lobbying filings matched to AC Immune SA.